Showing 1 - 20 results of 2,777 for search '(( ct ((values decrease) OR (larger decrease)) ) OR ( i when decrease ))', query time: 0.45s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Trypanosome locomotion with a decreased body stiffness of , which leads to an increase in both the swimming velocity and rotation frequency when compared to the reference case in S1V. by Florian A. Overberg (21402904)

    Published 2025
    “…<p>Trypanosome locomotion with a decreased body stiffness of , which leads to an increase in both the swimming velocity and rotation frequency when compared to the reference case in <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013111#pcbi.1013111.s003" target="_blank">S1V</a>.…”
  16. 16

    S1 File - by Abed al Hadi Krisht (19704098)

    Published 2024
    “…Extent of the lesion of more than 75% was independently associated with day-60 mortality (aHR = 1.72[1.06; 2.78], p = 0.03). The prediction of death at day 60 was improved when considering simultaneously biological and radiological markers obtained on ICU admission (AUC = 0.78).…”
  17. 17

    The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood. by Peng Liu (120506)

    Published 2025
    “…<p>The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood.…”
  18. 18

    Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible by Fulton F. Velez (9600028)

    Published 2025
    “…(acellular tissue engineered vessel-tyod [ATEV]) for extremity arterial trauma repair when autologous vein repair is not feasible.</p> <p>The 3-year budget impact of adding ATEV as a repair option alongside autologous vein, prosthetic graft, and “non-autologous other” grafts was evaluated from the perspectives of a Level I trauma center and third-party commercial payers. …”
  19. 19
  20. 20